Yifan Xinfu Pharmaceutical Co Ltd (002019) - Total Liabilities
Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has total liabilities worth CN¥4.08 Billion CNY (≈ $597.66 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002019 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Yifan Xinfu Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Yifan Xinfu Pharmaceutical Co Ltd asset portfolio.
Yifan Xinfu Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pebblebrook Hotel Trust
NYSE:PEB
|
USA | $2.77 Billion |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
China | CN¥6.91 Billion |
|
FLEX LNG Ltd
NYSE:FLNG
|
USA | $1.89 Billion |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €30.18 Million |
|
Molymet
SN:MOLYMET
|
Chile | CL$878.73 Million |
|
China Tianying Inc
SHE:000035
|
China | CN¥21.26 Billion |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
China | CN¥31.41 Billion |
|
DCM Shriram Limited
NSE:DCMSHRIRAM
|
India | Rs-77.33 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Yifan Xinfu Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Yifan Xinfu Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yifan Xinfu Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yifan Xinfu Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.13 Billion ≈ $604.94 Million |
+7.13% |
| 2024-12-31 | CN¥3.86 Billion ≈ $564.69 Million |
+18.93% |
| 2023-12-31 | CN¥3.24 Billion ≈ $474.80 Million |
-4.50% |
| 2022-12-31 | CN¥3.40 Billion ≈ $497.15 Million |
+0.20% |
| 2021-12-31 | CN¥3.39 Billion ≈ $496.16 Million |
+13.44% |
| 2020-12-31 | CN¥2.99 Billion ≈ $437.38 Million |
-7.87% |
| 2019-12-31 | CN¥3.24 Billion ≈ $474.71 Million |
+12.36% |
| 2018-12-31 | CN¥2.89 Billion ≈ $422.49 Million |
+45.42% |
| 2017-12-31 | CN¥1.99 Billion ≈ $290.54 Million |
-35.60% |
| 2016-12-31 | CN¥3.08 Billion ≈ $451.13 Million |
+85.03% |
| 2015-12-31 | CN¥1.67 Billion ≈ $243.81 Million |
+110.58% |
| 2014-12-31 | CN¥791.21 Million ≈ $115.78 Million |
+174.54% |
| 2013-12-31 | CN¥288.20 Million ≈ $42.17 Million |
-50.37% |
| 2012-12-31 | CN¥580.73 Million ≈ $84.98 Million |
-16.65% |
| 2011-12-31 | CN¥696.73 Million ≈ $101.95 Million |
+39.97% |
| 2010-12-31 | CN¥497.79 Million ≈ $72.84 Million |
+118.99% |
| 2009-12-31 | CN¥227.31 Million ≈ $33.26 Million |
-20.35% |
| 2008-12-31 | CN¥285.39 Million ≈ $41.76 Million |
-15.03% |
| 2007-12-31 | CN¥335.87 Million ≈ $49.15 Million |
+25.36% |
| 2006-12-31 | CN¥267.92 Million ≈ $39.21 Million |
+36.68% |
| 2005-12-31 | CN¥196.02 Million ≈ $28.68 Million |
+302.32% |
| 2004-12-31 | CN¥48.72 Million ≈ $7.13 Million |
-53.48% |
| 2003-12-31 | CN¥104.73 Million ≈ $15.32 Million |
+99.37% |
| 2002-12-31 | CN¥52.53 Million ≈ $7.69 Million |
+49.85% |
| 2001-12-31 | CN¥35.05 Million ≈ $5.13 Million |
-- |
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provi… Read more